blue-20211015

0001293971-21-000078.txt : 20211018 0001293971-21-000078.hdr.sgml : 20211018 20211018090635 ACCESSION NUMBER: 0001293971-21-000078 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211015 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211018 DATE AS OF CHANGE: 20211018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 211327439 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 8-K 1 blue-20211015.htm 8-K blue-20211015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________

FORM 8-K

__________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2021

__________________________

bluebird bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

_____________________________________________________________


Delaware	001-35966	13-3680878
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

60 Binney Street, Cambridge, MA		02142
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (339) 499-9300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_____________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	BLUE	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective October 15, 2021, the board of directors (the “Board”) of bluebird bio, Inc. (the “Company”) appointed Elisabeth Leiderman, M.D. to the Board as a Class I director and increased the size of the Board to twelve. Dr. Leiderman will serve as the chair of the audit committee of the Board, effective upon the consummation of the planned separation of the Company’s oncology programs and portfolio from its severe genetic disease programs and portfolio through the spinoff of 2seventy bio, Inc., as an independent, publicly-traded Delaware corporation.

Since September 2020, Elisabeth Leiderman, M.D. has served as Chief Financial Officer and Head of Corporate Development for Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, with its headquarters in Boston, Massachusetts and is listed on Nasdaq. Before joining Decibel, from January 2020 to August 2020, Dr. Leiderman served as Chief Business Officer for Complexa, Inc., a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases. Prior to Complexa, Dr. Leiderman was Senior Vice President, Head of Corporate Development at Fortress Biotech from November 2016 to November 2019. Earlier in her career from 2007 to 2016, Dr. Leiderman developed her transaction and capital markets expertise in the healthcare investment banking groups at Nomura, Credit Suisse, Jefferies and UBS. Dr. Leiderman began her career in medical affairs at AstraZeneca, where she analyzed product and industry trends related to the central nervous system. Dr. Leiderman earned an M.D. from the Sackler School of Medicine at Tel Aviv University, an MBA from The Wharton School at the University of Pennsylvania and a B.A. from The University of Pennsylvania.

In connection with her appointment, on October 15, 2021, the Company granted Dr. Leiderman a stock option to purchase 7,500 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a purchase price equal to the closing price per share of the Common Stock on the NASDAQ Global Select Market on October 15, 2021. Dr. Leiderman was also granted on October 15, 2021 restricted stock units for 4,663 shares of Common Stock. The stock options and restricted stock units vest ratably over three years in annual installments.

Dr. Leiderman is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements of understandings between Dr. Leiderman and any other persons pursuant to which she was elected as a director.

Item 8.01 Other Events.

In connection with the planned separation of the Company and 2seventy bio, Inc. (“2seventy”) into two independent, publicly traded companies, October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to the Company’s stockholders in order to effect the separation. Each stockholder of record as of the close of business on October 19, 2021 will receive, on the distribution date, one share of 2seventy common stock for every three shares of the Company’s common stock held. The share dividend is expected to be distributed to the Company’s stockholders on or about November 4, 2021. Following the separation, the Company’s stockholders will also receive cash in lieu of any fractional shares of 2seventy common stock that those holders would have received after application of the above ratio.

On October 18, 2021 the Securities and Exchange Commission declared 2seventy’s Registration Statement on Form 10 (the “Form 10”) effective. The completion of the separation is subject to certain conditions described in the Form 10, including those conditions set forth in the Separation Agreement to be entered into between the Company and 2seventy, the form of which is filed as an exhibit to the Form 10. No action is required by the Company’s stockholders in order to receive the shares of 2seventy common stock in the dividend distribution.

“When-issued” trading for 2seventy common stock and “ex-distribution” trading for the Company’s common stock is expected to commence on October 18, 2021 under the stock ticker symbols “TSVTV” and “BLUEV”, respectively. A description of these expected trading markets is included in the Form 10. After the separation, 2seventy common stock is expected to trade on the Nasdaq Global Select Market under the stock ticker symbol “TSVT” and the Company will continue to trade on Nasdaq Global Select Market under the stock ticker symbol “BLUE.”

On October 18, 2021, the Company issued a press release regarding the matters described in this Current Report on Form 8-K. The full text of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This Current Report on Form 8-K contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, structure, timing and terms of the planned separation, the distribution and markets for bluebird and 2seventy stock. Each forward-looking statement is subject to risks and uncertainties that could cause actual events to differ materially from those expressed or implied in such statement.

Applicable risks and uncertainties include those related to the possibility that bluebird may not complete the separation on the terms or timing currently contemplated, if at all; and the risks listed under the heading “Risk Factors” and elsewhere in bluebird’s Annual Report on Form 10-K filed with the SEC on February 23, 2021, and in bluebird’s subsequent SEC filings, including SEC filings related to the planned separation, and in the Form 10. These forward-looking statements (except as otherwise noted) speak only as of the date of this Current Report on Form 8-K, and bluebird undertakes no obligation to update these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description
99.1						Press release issued by bluebird bio, Inc. on October 18 , 2021 .
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: October 18, 2021	bluebird bio, Inc.

	By:	/s/ Jason F. Cole
		Jason F. Cole
		Chief Operating and Legal Officer

EX-99.1 2 exhibit99120211018.htm EX-99.1 Document

Exhibit 99.1

bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 18, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies.

Each bluebird bio stockholder of record as of the close of business on October 19, 2021 will receive, on the distribution date, one share of 2seventy common stock for every three shares of bluebird common stock held. The share dividend is expected to be distributed to bluebird stockholders on or about November 4, 2021. Following the separation, bluebird stockholders will also receive cash in lieu of any fractional shares of 2seventy common stock that those holders would have received after application of the 3:1 distribution ratio. No action is required by bluebird stockholders in order to receive the shares of 2seventy common stock in the dividend distribution.

Additionally, on October 18, 2021 the Securities and Exchange Commission declared 2seventy’s Registration Statement on Form 10 (the “Form 10”) effective. This Form 10 contains further information regarding bluebird bio’s plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company, including the conditions to completion of the separation.

“When-issued” trading for 2seventy common stock and “ex-distribution” trading for bluebird common stock is expected to commence on October 18, 2021 under the stock ticker symbols “TSVTV” and “BLUEV”, respectively. A description of these expected trading markets is included in the Form 10. After the separation, 2seventy common stock is expected to trade on the Nasdaq Global Select Market under the stock ticker symbol “TSVT” and bluebird will continue to trade on Nasdaq Global Select Market under the stock ticker symbol “BLUE.”

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has an additional nest in Seattle, Wash. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.; 2seventy and 2seventy bio are trademarks of bluebird bio, Inc. until completion of the separation.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: statements about the expected timing for completion of the distribution and separation; the tax free nature of the separation. Applicable risks and uncertainties include those related to the possibility that bluebird bio and 2seventy bio may not

complete the separation on the terms or timeline currently contemplated if at all, achieve the expected benefits of the separation, and that the separation could harm bluebird bio and/or 2seventy bio business, results of operations and financial condition; the risk that the transaction might not be tax-free; the risk that bluebird bio and 2seventy bio may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as independent companies; 2seventy’s lack of independent operating history and the risk that its accounting and other management systems may not be prepared to meet the financial reporting and other requirements of operating as an independent public company; the risk that dedicated financial and/or strategic funding sources may not be available on favorable terms; the risk that the separation may adversely impact bluebird bio’s or 2seventy bio’s ability to attract or retain key personnel; the risk that the separation may adversely impact the effectiveness of development and commercialization efforts by bluebird bio and/or 2seventy bio and their respective partners; the risk of possible disruption to bluebird bio’s businesses as a result of the announcement or pendency of the separation; the risk that BLAs will not be accepted for filing by the FDA on the expected timeline, and the risk that bluebird bio and/or 2seventy bio do not receive regulatory approval for product candidates on the timeline that bluebird bio and/or 2seventy bio expect, or at all; and the risk that bluebird bio and/or 2seventy bio are unable to manage their operating expenses or cash use for operations. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that bluebird bio and 2seventy bio may not complete the separation on the terms or timeline currently contemplated if at all, achieve the expected benefits of a separation, and a separation could harm bluebird bio’s and/or 2seventy bio’s business, results of operations and financial condition; the risk that the transaction might not be tax-free; bluebird bio and/or 2seventy bio may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as independent companies; 2seventy bio's lack of independent operating history and the risk that its accounting and other management systems may not be prepared to meet the financial reporting and other requirements of operating as an independent public company; dedicated financial and/or strategic funding sources may not be available on favorable terms; a separation or announcement thereof may adversely impact bluebird bio’s ability to attract or retain key personnel; a separation may adversely impact the effectiveness of development and commercialization efforts by bluebird bio and/or 2seventy bio and their respective partners; bluebird bio’s businesses may be disrupted as a result of the announcement or pendency of the separation; and the risk that bluebird bio is unable to realize the intended benefits of resizing and reshaping its workforce. For a discussion of other risks and uncertainties, and other important factors, any of which could cause bluebird bio’s and/or 2seventy bio’s actual results to differ from those contained in the forward-looking statements, see the sections entitled “Risk Factors” in the Form 10 and in bluebird bio’s most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in bluebird bio’s and 2seventy bio’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and neither bluebird bio nor 2seventy bio undertake any duty to update this information unless required by law.

Investors & Media

For bluebird bio

Investors:

Courtney O’Leary, 978-621-7347

coleary@bluebirdbio.com

Media:

Sarah Alspach, 857-299-6198

sarah.alspach@bluebirdbio.com

For 2seventy bio

Investors:

Elizabeth Pingpank, 860-463-0469

epingpank@bluebirdbio.com

Media:

Jenn Snyder, 617-448-0281

jsnyder@bluebirdbio.com

Source: bluebird bio, Inc.

EX-101.SCH 3 blue-20211015.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 blue-20211015_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover page. Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 5 blue-20211015_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 blue-20211015_htm.xml IDEA: XBRL DOCUMENT 0001293971 2021-10-15 2021-10-15 0001293971 false 8-K 2021-10-15 bluebird bio, Inc. DE 001-35966 13-3680878 60 Binney Street Cambridge MA 02142 339 499-9300 false false false false Common Stock, $0.01 par value per share BLUE NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 15, 2021
Cover [Abstract]
Document Period End Date	Oct. 15, 2021
Entity Registrant Name	bluebird bio, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-35966
Entity Tax Identification Number	13-3680878
Entity Address, Address Line One	60 Binney Street
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	339
Local Phone Number	499-9300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	BLUE
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001293971
Amendment Flag	false
Document Type	8-K

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.bluebirdbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports blue-20211015.htm blue-20211015.xsd blue-20211015_lab.xml blue-20211015_pre.xml exhibit99120211018.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "blue-20211015.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "blue-20211015.htm" ] }, "labelLink": { "local": [ "blue-20211015_lab.xml" ] }, "presentationLink": { "local": [ "blue-20211015_pre.xml" ] }, "schema": { "local": [ "blue-20211015.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blue", "nsuri": "http://www.bluebirdbio.com/20211015", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211015.htm", "contextRef": "i6bd924048bb14e57aeed5f120e88dc93_D20211015-20211015", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.bluebirdbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211015.htm", "contextRef": "i6bd924048bb14e57aeed5f120e88dc93_D20211015-20211015", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001293971-21-000078-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001293971-21-000078-xbrl.zip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end